Travere Therapeutics director Gary A. Lyons disposes of USD 629,150 in common sharesPUBT·25 minutes agoTVTX+3.22%
Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains MomentumAsian Corporate Newswire·15 hours ago01952-18.72%TVTX+3.22%
97,573 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Rice Hall James & Associates LLCMarket Beat·1 day ago, 05:00 AMTVTX+3.22%
Travere Therapeutics posts corporate overview on rare kidney disease growth strategy, FILSPARI expansion and pipeline updatesPUBT·Aug 13 at 06:14 PMTVTX+3.22%
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock NewsStockTitan·Aug 12 at 08:00 AMTVTX+3.22%
Travere Therapeutics, Inc. $TVTX Shares Bought by Quantinno Capital Management LPMarket Beat·Aug 12 at 03:24 AMTVTX+3.22%STT-3.16%
This biotech dealmaker — tied to Merck, Travere — is in a profit-taking zoneMSN·Aug 6 at 03:21 PMLGND+1.08%TVTX+3.22%
Biotech Stocks At 52-Week Highs - BVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRSrttnews·Aug 6 at 03:55 AMACRS+2.14%CRL+3.87%
Regulatory Uncertainty Threatens Travere Therapeutics’ Cross-Border Deals and PartnershipsTip Ranks·Aug 6 at 01:01 AMTVTX+3.22%
Travere Therapeutics to present at Canaccord Genuity Growth ConferencePUBT·Aug 5 at 04:48 PMTVTX+3.22%C-3.46%
Does FILSPARI-Driven Revenue Growth And Wider Losses Change The Bull Case For Travere Therapeutics (TVTX)?Simplywall·Aug 5 at 02:16 PMTVTX+3.22%
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga_article·Aug 5 at 07:05 AMJUNS-5.14%OFIX+2.54%
Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $65, Implies 16% UpsideTradingView·Aug 5 at 04:20 AMTVTX+3.22%
Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going Onbenzinga_article·Aug 5 at 02:16 AMTVTX+3.22%
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga_article·Aug 4 at 04:06 PMRIGL+7.66%AMIX-4.21%
